Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — ASX Small & Mid-Cap Conference 2021
19 slides from Nova Eye Medical's conference presentation, Sep 14, 2021
Slide 1: Nova Eye Medical Limited (ASX:EYE)
1 First iTrack ™ surgical case performed in MAGIC Study. David Lubeck, MD (left) and Shamil Patel, MD, MBA (right). Nova Eye Medical Limited (ASX:EYE) ASX Small & Mid-Cap Conference 14 September 2021
Slide 2: Disclaimer
2 Disclaimer: This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any
Slide 3: ASX:EYE Business Snapshot
3 ASX:EYE BUSINESS SNAPSHOT Nova Eye Medical Limited (ASX:EYE) comprises two business units, glaucoma and AMD/2RT® – these segments address the leading causes of blindness in the developed world. Nova Eye Medical, Glaucoma AlphaRET, AMD Develop, market and sell comprehensive portfolio Strategy Progr
Slide 4: Corporate Snapshot
4 ASX:EYE CORPORATE SNAPSHOT Nova Eye Medical Limited Exchange Australian Securities Exchange Ticker EYE Management + Board Ownership 12% Shares on Issue 143.6 million Revenues (12 months to June 2021) A$13.4 million US$ 9.7 million1 Net Tangible Assets (at 30 June 2021) A$35.3 million US$26.12 mill
Slide 5: Glaucoma
5 GLAUCOMA
Slide 6: Glaucoma Market
6 GLAUCOMA MARKET Glaucoma is the leading cause of irreversible blindness and the second leading cause of blindness worldwide. The aging global population is driving glaucoma prevalence and provides a strong platform for business growth. 131.9 million* ▪ Advancements in diagnostic and imaging techno
Slide 7: The Glaucoma Treatment Spectrum
7 THE GLAUCOMA TREATMENT SPECTRUM The treatment paradigm for glaucoma has been transformed over the past 5 years with the introduction of minimally invasive glaucoma surgery (MIGS) which, combined with ageing demographics, provides a strong platform for future market growth. MILD MODERATE SEVERE VIS
Slide 8: Nova Eye Medical Across the Glaucoma Treatment Spectrum
8 NOVA EYE MEDICAL ACROSS THE GLAUCOMA TREATMENT SPECTRUM We are expanding our glaucoma treatment portfolio to address the full spectrum of the disease process, adding new products and indications to better meet the treatment needs of comprehensive ophthalmologists and glaucoma specialists. MILD MOD
Slide 9: FY21 Glaucoma Highlights
9 FY21 GLAUCOMA HIGHLIGHTS In FY21 we executed several initiatives to drive market awareness of the iTrack™ MIGS device, which resulted in sales growth but, more importantly, set the foundation for further growth in FY22 and beyond. The US publication “Glaucoma Physician” (circulation +20,000 ophtha
Slide 10: iTrack microcatheter technology offers a number of clinical advantages
10 Our proprietary iTrack™ microcatheter technology offers a number of clinical advantages over other glaucoma treatments and MIGS devices for mild to moderate glaucoma. Today, iTrack ™ is recognized as a ▪ The world’s first canaloplasty device. key player in the MIGS market and is positioned for st
Slide 11: iTrack Safety Compared with iStent (GKOS)
11 iTRACK™ SAFETY COMPARED WITH iSTENT® (GKOS) The unique stent-free, tissue sparing mechanism of iTrack™ re-establishes natural aqueous flow to effectively reduce IOP while also preserving the health of the corneal endothelium. At American Society of Cataract and Refractive Surgeons Congress 2021 d
Slide 12: FY21 Glaucoma Operating Result
12 FY21 GLAUCOMA OPERATING RESULT Material improvement in operating result was underpinned by a 25% increase in global sales compared to the pcp, including the addition of Molteno3® sales, and a reduction in operating costs. A$’000s (year ended 30 June) US$’000s (year ended 30 June)1 FY20 FY21 Growt
Slide 13: 2RT, Intermediate AMD
13 2RT®, INTERMEDIATE AMD 2RT® (AlphaRET) is a proprietary, world-first nanosecond laser therapy to treat intermediate AMD (iAMD) While there have been major advances in the treatment of AMD in its late stages (referred to as Wet AMD), there has been little progress in the treatment of AMD in its ea
Slide 14: Health of retina & macula
14 Normal Vision Morbidity Health of retina & macula AMD progression without 2RT 2RT application to defer progression Visual difficulty requiring Anti VEGF injections for wet form Approx 75 years old
Slide 15: Advances in treatment of AMD in its late stages
15 While there have been major advances in the treatment of AMD in its late stages (referred to as Wet AMD), there has been little progress in the treatment of AMD in its early stages . ▪ 300 person clinical study conducted in Australia and Europe demonstrated that 2RT® reduced the rate of disease p
Slide 16: 2RT Market Assessment
16 2RT® MARKET ASSESSMENT Our proprietary 2RT® nanosecond laser therapy is a world-first intervention designed to treat intermediate AMD. There is currently no treatment (drugs or devices) for the treatment of intermediate AMD. Population with Patients who do not meet Estimated population Early/Inte
Slide 17: FY21 Group Cash Flow
17 FY21 GROUP CASH FLOW A$ million US$ million1 (year ended 30 June 2021) (year ended 30 June 2021) Cash generated/ (used) from operations (4.1) (3.0) (Deduct): Expenditure on 2RT (IDE) (1.1) (0.8) Repayment of leases (0.4) (0.3) New product development (0.7) (0.5) Plant and equipment acquired (0.6)
Slide 18: Nova Eye Group Outlook
18 NOVA EYE GROUP OUTLOOK Subject to change due to COVID, Nova Eye Medical Limited is well positioned to propel growth of its glaucoma consumable surgical devices through FY2022 1 USA Sales Focus: significant investment in glaucoma consumable surgical device sales, marketing and clinical development
Slide 19: Contact
19 CONTACT Tom Spurling Tom Duthy, PhD Kate Hunt Managing Director Investor Relations and Head of Marketing Corporate Development M: +61 404 080 679 W: +61 8 8362 0193 M: +61 402 493 727 E: khunt@nova-eye.com E: tspurling@nova-eye.com E: tduthy@nova-eye.com
Nova Eye Medical — ASX Small & Mid-Cap Conference 2021 on 6ix